.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

FROVA Drug Profile

« Back to Dashboard
Frova is a drug marketed by Endo Pharms, Glenmark Pharms Ltd, and Mylan Pharms Inc. and is included in three NDAs. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in thirty-three countries.

The generic ingredient in FROVA is frovatriptan succinate. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the frovatriptan succinate profile page.

Summary for Tradename: FROVA

Patents:2
Applicants:3
NDAs:3
Suppliers / Packagers: see list5

Clinical Trials for: FROVA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,464,864<disabled> <disabled>
Mylan Pharms Inc
FROVATRIPTAN SUCCINATE
frovatriptan succinate
TABLET;ORAL202931-001Aug 28, 2014RXNo<disabled><disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,827,871<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FROVA

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,618,948<disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,464,864<disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 20015,917,054<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FROVA

Drugname Dosage Strength RLD Submissiondate
frovatriptan succinateTablets2.5 mgFrova3/9/2011

Non-Orange Book Patents for Tradename: FROVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,637,611 Medicaments<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FROVA

Country Document Number Estimated Expiration
Norway2005011<disabled in preview>
Czech Republic9302861<disabled in preview>
South Africa9204658<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FROVA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0591280/01Switzerland<disabled>FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
C0019France<disabled>PRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
C/GB03/014United Kingdom<disabled>PRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc